SCHEDULE: Summit Partners Discloses 3.04% Stake in GeneDx

Summit Partners and its affiliates have disclosed a 3.04% beneficial ownership stake in GeneDx Holdings Corp. Class A common stock, totaling 867,265 shares.

Summary

• Summit Partners Public Asset Management, LLC and its affiliates, including various funds and individuals, reported beneficial ownership of GeneDx Holdings Corp. Class A common stock.
• The aggregate amount beneficially owned by the primary reporting persons is 867,265 shares.
• This represents 3.04% of the Class A common stock outstanding.
• The ownership percentage is calculated based on 28,553,204 outstanding shares as of April 23, 2025, as reported in the issuer's Quarterly Report on Form 10-Q.
• The filing explicitly states that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.
• Summit Partners Public Asset Management, LLC acts as the investment manager for the shares and call options held by several funds (Summit Concentrated Growth, Summit Technology, SPSO Limited, SPSO QP, SPSO LP) and a separately managed account.
• Philip Furse, Timothy Albright, Robert MacAulay, and Matthew Curtis are associated with Summit Partners Public Asset Management, LLC and are deemed beneficial owners due to their roles as Chief Investment Officer, Portfolio Managers, and Chief Risk Officer, respectively.

Sentiment

Score: 5

Explanation: Neutral, as this is a factual disclosure of passive ownership and does not contain performance or forward-looking statements about the issuer.

Positives

• A significant institutional investor, Summit Partners, holds a stake, which could be seen as a vote of confidence in GeneDx Holdings Corp.
• The filing explicitly states the stake is passive and not for control, reducing concerns about potential activist intervention or disruptive changes to company strategy.

Risks

• The filing itself does not detail risks related to GeneDx Holdings Corp.'s business operations or financial performance.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, mitigating typical risks associated with large ownership disclosures.

Future Outlook

NA

Industry Context

This filing indicates continued institutional interest in the healthcare and genomics sector, specifically in GeneDx Holdings Corp. It reflects a passive investment strategy by Summit Partners, a known growth equity firm, suggesting a belief in the long-term value of the company without seeking active management influence.

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional holder's passive stake in the company.
• Company Management: Awareness of a large, passive institutional investor holding a stake in the company.

Key Dates

Keywords

GeneDx Holdings Corp, Summit Partners, SEC filing, Schedule 13G, beneficial ownership, Class A common stock, institutional investment, passive stake, equity